查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1424829

藥物基因組學市場：按產品、技術、應用、最終用戶劃分 - 全球預測（至 2031 年）

Pharmacogenomics Market by Offering (Instrument, Consumables, Software), Technology (PCR, Sequencing, Microarray), Application (Oncology, Mental Health, Cardiology, Neurology, Infectious Disease), End User (Hospitals, Academic) - Global Forecast to 2031
出版日期: | 出版商: Meticulous Research | 英文 210 Pages | 訂單完成後即時交付

價格

到 2030 年，藥物基因組學市場預計將達到 195 億美元，2024 年至 2031 年複合年增長率為 8.9%。

該報告透過廣泛的一手和二手研究以及對市場情景的深入分析，探討了關鍵的行業驅動因素、限制因素、挑戰和機遇。 藥物基因組學市場的成長是由於藥物基因組學生物標記治療應用的擴大、個性化藥物採用的擴大、老年人口的增加和慢性病的患病率以及藥物發現和開發的增加美國FDA 和EMA，其中包括藥物基因組學資料使用的建議。 然而，個人化藥物的高成本限制了該市場的成長。

此外，藥物基因組學在神經系統疾病和癌症治療中的應用不斷擴大，準確度更高的新的、更先進的診斷工具的開發，以及對藥物不良反應的認識不斷增強，正在推動藥物基因組學市場的活動。預計這將為玩家提供成長機會。 然而，對藥物基因組學和個人化醫療的認識不足、對基因檢測及其益處缺乏了解以及缺乏對基因檢測和精準醫療的報銷是影響市場成長的主要挑戰。

目錄

第1章簡介

第2章研究方法

第 3 章執行摘要

第 4 章市場洞察

  • 摘要
  • 影響市場成長的因素
    • 市場動態
    • 因素分析
  • 主要趨勢
    • 隨著定序成本的下降，藥物基因組學測試變得更加經濟實惠
    • 人工智慧在藥物基因組學領域的潛力不斷增長
  • 監理分析
    • 美國
    • 加拿大
    • 歐洲
    • 中國
    • 日本
    • 印度
    • 拉丁美洲
    • 中東/非洲
  • 價格分析
  • 波特五力分析

第 5 章藥物基因體學市場評估：依產品

  • 摘要
  • 消耗品
  • 設備
  • 軟體與服務

第 6 章藥物基因體學市場評估：依技術

  • 摘要
  • 聚合□鍊式反應 (PCR)
  • 定序
  • 微陣列晶片
  • 質譜分析
  • 電泳
  • 其他技術

第 7 章全球藥物基因體學市場評估：按應用

  • 摘要
  • 癌症領域
  • 心理健康
  • 傳染病
  • 循環系統
  • 神經系統疾病
  • 其他用途

第 8 章藥物基因體學市場評估：按最終使用者

  • 摘要
  • 醫院/診斷實驗室
  • 學術/研究機構
  • 其他最終用戶

第 9 章藥物基因體學市場評估：按地區

  • 概述
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 亞太地區其他地區
  • 拉丁美洲
  • 中東/非洲

第10章競爭分析

  • 摘要
  • 主要成長策略
  • 競爭基準測試
  • 競爭對手儀表板
    • 行業領導者
    • 市場差異化因素
    • 領先企業
    • 新興公司
  • 市場排名（2023 年）
    • Thermo Fisher Scientific, Inc.（美國）
    • Illumina, Inc.（美國）
    • 丹納赫公司（美國）
    • F. Hoffmann-La Roche Ltd.（瑞士）

第 11 章公司簡介（業務概覽、財務概況、產品組合、策略發展、SWOT 分析）

  • F. Hoffmann La-Roche Ag
  • Thermo Fisher Scientific, Inc.
  • Illumina, Inc.
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Qiagen N.V.
  • Abbott Laboratories
  • Bio-Rad Laboratories, Inc.
  • PerkinElmer, Inc.
  • Pacific Biosciences of California, Inc.

（附註：將發布前 5 名公司的 SWOT 分析。）

第12章 附錄

Product Code: MRHC - 104682

The pharmacogenomics market is expected to reach $19.5 billion by 2030, at a CAGR of 8.9% from 2024 to 2031.

With extensive primary and secondary research and in-depth analysis of the market scenario, the report studies the key industry drivers, restraints, challenges, and opportunities. The growth of the pharmacogenomics market is attributed to the growing therapeutic applications of pharmacogenomic biomarkers, the increasing adoption of personalized medicines, the rising geriatric population and chronic disease prevalence, and the U.S. FDA's and EMA's recommendations for using pharmacogenomic data in drug discovery & development. However, the high costs of personalized medicines restrain the growth of this market.

Furthermore, the increasing application of pharmacogenomics in the treatment of neurological disorders and cancers, the development of new, more advanced diagnostic tools with improved accuracy, and growing awareness regarding adverse drug reactions are expected to generate growth opportunities for the players operating in the pharmacogenomics market. However, low awareness about pharmacogenomics and personalized medicine, the limited understanding of genetic testing and its benefits, and the lack of reimbursements for genetic testing and precision medicine are major challenges impacting market growth.

Based on offering, the global pharmacogenomics market is segmented into consumables, instruments, and software & services. In 2024, the consumables segment is expected to account for the largest share of the market. The largest market share of this segment is attributed to the recurrent use of consumables over instruments and the high burden of chronic diseases. Moreover, the high increasing prevalence of chronic diseases coupled with the focus of players for the launch of advanced and better reagents & kits drives the segment growth.

Based on technology, the global pharmacogenomics market is segmented into polymerase chain reaction (PCR), sequencing, microarray, mass spectrometry, electrophoresis, and other technologies. In 2024, the polymerase chain reaction (PCR) segment is expected to account for the largest share of the pharmacogenomics market. The large market share of this segment is attributed to the high sensitivity, accuracy, low sample volume requirements, and cost-effectiveness coupled with the high presence of PCR base across all the end users, initiatives by players to launch and get approvals for new PCR products for pharmacogenomics, and a wide range of applications of the PCR.

Based on application, the global pharmacogenomics market is segmented into oncology, mental health cardiology, neurological disorders, infectious diseases, and other applications. The oncology segment is expected to register the fastest CAGR during the forecast period of 2024-2031. The fast growth of this segment is attributed to the increasing prevalence of cancer cases and the need for targeted cancer treatment, growing demand for precision oncology, and growing research activities for precision oncology.

Based on end user, the global pharmacogenomics market is segmented into hospitals & diagnostic laboratories, academic and research institutes, and other end users. In 2024, the hospitals & diagnostic laboratories segment is expected to account for the largest share of the global pharmacogenomics Market. The large market share of this segment is attributed to the growing adoption of precision medicine, the growing prevalence of chronic diseases, the large number of clinical trials conducted at hospitals and diagnostic laboratories, and the focus of pharmacogenomic testing services companies on acquisitions and launches of pharmacogenomic testing services. For instance, in 2023, Incite Health Pty Limited (Australia), a pharmacogenomic testing company, acquired CNSDose LLC (U.S.), a pharmacogenomic test provider.

An in-depth analysis of the geographical scenario of the pharmacogenomics market provides detailed qualitative and quantitative insights into five major geographies: North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa, along with the coverage of major countries in each region. Asia-Pacific is slated to register the highest CAGR during the forecast period. Rising government spending to increase testing capacities; increasing cases of inherited diseases such as Down Syndrome, cystic fibrosis, sickle cell disease, colon (colorectal) cancer, and breast cancer; growing awareness about the significance of genetic tests; and increasing government initiatives promoting genetic testing contribute to the growth of the market.

Some of the key players operating in the global pharmacogenomics market are F. Hoffmann-La Roche AG (Switzerland), Abbott Laboratories (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Illumina, Inc. (U.S.), PerkinElmer, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Danaher Corporation (U.S.), QIAGEN N.V. (Netherlands), and Pacific Biosciences of California, Inc. (U.S.).

Scope of the Report:

Pharmacogenomics Market, by Offering

  • Instruments
  • Consumables
  • Software & Services

Pharmacogenomics Market, by Technology

  • Polymerase Chain Reaction
  • DNA Sequencing
  • Electrophoresis
  • Microarray
  • Mass Spectrometry
  • Other Technologies

(Note: Other Technologies include nucleic acid amplification technology and in situ hybridization)

Pharmacogenomics Market, by Application

  • Oncology
  • Mental Health
  • Cardiology
  • Neurological Disorders
  • Infectious Diseases
  • Other Applications

(Note: Other Applications include pain management, adverse drug reactions, autoimmune diseases, metabolic disorders, pulmonary diseases, hematology, dermatology, transplantation, urology, analgesia, anesthesiology, antidotal therapy, and forensic pathology)

Pharmacogenomics Market, by End User

  • Hospitals & Diagnostic Laboratories
  • Academic & Research Institutes
  • Other End Users

(Other End Users include pharmaceutical & biotechnology companies, clinical research organizations (CROS), and forensic laboratories)

Pharmacogenomics Market, by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Rest of Europe (RoE)
  • Asia-Pacific (APAC)
    • Japan
    • China
    • India
    • Rest of Asia-Pacific (RoAPAC)
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America (RoLATAM)
  • Middle East & Africa

TABLE OF CONTENTS

1. Introduction

  • 1.1. Market Definition & Scope
  • 1.2. Market Ecosystem
  • 1.3. Currency & Limitations
  • 1.4. Key Stakeholders

2. Research Methodology

  • 2.1. Research Approach
  • 2.2. Process Of Data Collection and Validation
    • 2.2.1. Secondary Research
    • 2.2.2. Primary Research/Interviews with Key Opinion Leaders from The Industry
  • 2.3. Market Sizing and Forecasting
    • 2.3.1. Market Size Estimation Approach
    • 2.3.2. Growth Forecast Approach
  • 2.4. Assumptions For the Study

3. Executive Summary

4. Market Insights

  • 4.1. Overview
  • 4.2. Factors Affecting Market Growth
    • 4.2.1. Market Dynamics
      • 4.2.1.1. Growing Therapeutic Applications of Pharmacogenomic Biomarkers Supporting Market Growth
      • 4.2.1.2. Increasing Adoption of Personalized Medicines Driving the Demand for Pharmacogenomics
      • 4.2.1.3. Rising Geriatric Population and Chronic Disease Prevalence Boosting Pharmacogenomic Research and Testing
      • 4.2.1.4. The U.S. FDA's And EMA's Recommendations for Using Pharmacogenomic Data in Drug Discovery & Development Accelerating Market Expansion
      • 4.2.1.5. Growing Awareness Regarding Adverse Drug Reactions (ADRs) Generating Opportunities for Market Players
      • 4.2.1.6. Low Awareness About Pharmacogenomics and Personalized Medicine to Remain a Major Challenge for Market Stakeholders
      • 4.2.1.7. Lack Of Reimbursements for Genetic Testing and Precision Medicine Impacting Market Growth
    • 4.2.2. Factors Analysis
  • 4.3. Key Trends
    • 4.3.1. Declining Costs of Sequencing Making Pharmacogenomic Testing More Affordable
    • 4.3.2. Increasing Potential of AI In Pharmacogenomics
  • 4.4. Regulatory Analysis
    • 4.4.1. U.S
    • 4.4.2. Canada
    • 4.4.3. Europe
    • 4.4.4. China
    • 4.4.5. Japan
    • 4.4.6. India
    • 4.4.7. Latin America
    • 4.4.8. Middle East & Africa
  • 4.5. Pricing Analysis
  • 4.6. Porter's Five Forces Analysis
    • 4.6.1. Bargaining Power of Buyers
    • 4.6.2. Bargaining Power of Suppliers
    • 4.6.3. Threat Of Substitutes
    • 4.6.4. Threat Of New Entrants
    • 4.6.5. Degree Of Competition

5. Pharmacogenomics Market Assessment-by Offering

  • 5.1. Overview
  • 5.2. Consumables
  • 5.3. Instruments
  • 5.4. Software & Services

6. Pharmacogenomics Market Assessment-by Technology

  • 6.1. Overview
  • 6.2. Polymerase Chain Reaction (PCR)
  • 6.3. Sequencing
  • 6.4. Microarray
  • 6.5. Mass Spectrometry
  • 6.6. Electrophoresis
  • 6.7. Other Technologies

7. Global Pharmacogenomics Market Assessment-by Application

  • 7.1. Overview
  • 7.2. Oncology
  • 7.3. Mental Health
  • 7.4. Infectious Diseases
  • 7.5. Cardiology
  • 7.6. Neurological Disorders
  • 7.7. Other Applications

8. Pharmacogenomics Market Assessment-by End User

  • 8.1. Overview
  • 8.2. Hospitals & Diagnostic Laboratories
  • 8.3. Academic & Research Institutes
  • 8.4. Other End Users

9. Pharmacogenomics Market Assessment-by Geography

  • 9.1. Overview
  • 9.2. North America
    • 9.2.1. U.S.
    • 9.2.2. Canada
  • 9.3. Europe
    • 9.3.1. Germany
    • 9.3.2. France
    • 9.3.3. U.K.
    • 9.3.4. Italy
    • 9.3.5. Spain
    • 9.3.6. Rest Of Europe
  • 9.4. Asia-Pacific
    • 9.4.1. China
    • 9.4.2. Japan
    • 9.4.3. India
    • 9.4.4. Rest Of Asia-Pacific
  • 9.5. Latin America
  • 9.6. Middle East & Africa

10. Competition Analysis

  • 10.1. Overview
  • 10.2. Key Growth Strategies
  • 10.3. Competitive Benchmarking
  • 10.4. Competitive Dashboard
    • 10.4.1. Industry Leaders
    • 10.4.2. Market Differentiators
    • 10.4.3. Vanguards
    • 10.4.4. Emerging Companies
  • 10.5. Market Ranking (2023)
    • 10.5.1. Thermo Fisher Scientific, Inc. (U.S.)
    • 10.5.2. Illumina, Inc. (U.S.)
    • 10.5.3. Danaher Corporation (U.S.)
    • 10.5.4. F. Hoffmann-La Roche Ltd. (Switzerland)

11. Company Profiles (Business Overview, Financial Snapshot, Product Portfolio, Strategic Developments, and SWOT Analysis)

  • 11.1. F. Hoffmann La-Roche Ag
  • 11.2. Thermo Fisher Scientific, Inc.
  • 11.3. Illumina, Inc.
  • 11.4. Danaher Corporation
  • 11.5. Agilent Technologies, Inc.
  • 11.6. Qiagen N.V.
  • 11.7. Abbott Laboratories
  • 11.8. Bio-Rad Laboratories, Inc.
  • 11.9. PerkinElmer, Inc.
  • 11.10. Pacific Biosciences of California, Inc.

(Note: SWOT Analysis of Top 5 Companies Will Be Provided)

12. Appendix

  • 12.1. Available Customization
  • 12.2. Related Reports
  • Table 1 Pharmacogenomics Instruments: Pricing
  • Table 2 Global Pharmacogenomics Market, by Offering, 2022-2031 (USD Million)
  • Table 3 Global Pharmacogenomic Consumables Market, by Country/Region, 2022-2031 (USD Million)
  • Table 4 Global Pharmacogenomic Instruments Market, by Country/Region, 2022-2031 (USD Million)
  • Table 5 Global Pharmacogenomic Software & Services Market, by Country/Region, 2022-2031 (USD Million)
  • Table 6 Advantages and Disadvantages of Technologies for Pharmacogenomics
  • Table 7 Global Pharmacogenomics Market, by Technology, 2022-2031 (USD Million)
  • Table 8 Global Pharmacogenomics Market for Polymerase Chain Reaction, by Country/Region, 2022-2031 (USD Million)
  • Table 9 Global Pharmacogenomics Market for Sequencing, by Country/Region, 2022-2031 (USD Million)
  • Table 10 Global Pharmacogenomics Market for Microarrays, by Country/Region, 2022-2031 (USD Million)
  • Table 11 Global Pharmacogenomics Market for Mass Spectrometry, by Country/Region, 2022-2031 (USD Million)
  • Table 12 Global Pharmacogenomics Market for Electrophoresis, by Country/Region, 2022-2031 (USD Million)
  • Table 13 Global Pharmacogenomics Market for Other Technologies, by Country/Region, 2022-2031 (USD Million)
  • Table 14 Global Pharmacogenomics Market, by Application, 2022-2031 (USD Million)
  • Table 15 Number of New Cancer Cases, by Region, 2020 Vs. 2040 (In Million)
  • Table 16 Global Pharmacogenomics Market for Oncology, by Country/Region, 2022-2031 (USD Million)
  • Table 17 Global Pharmacogenomics Market for Mental Health, by Country/Region, 2022-2031 (USD Million)
  • Table 18 HIV Statistics (2021)
  • Table 19 Global Pharmacogenomics Market for Infectious Diseases, by Country/Region, 2022-2031 (USD Million)
  • Table 20 Global Pharmacogenomics Market for Cardiology, by Country/Region, 2022-2031 (USD Million)
  • Table 21 Global Pharmacogenomics Market for Neurological Disorders, by Country/Region, 2022-2031 (USD Million)
  • Table 22 Global Pharmacogenomics Market for Other Applications, by Country/Region, 2022-2031 (USD Million)
  • Table 23 Global Pharmacogenomics Market, by End User, 2022-2031 (USD Million)
  • Table 24 Global Pharmacogenomics Market for Hospitals & Diagnostic Laboratories, by Country/Region, 2022-2031 (USD Million)
  • Table 25 Global Pharmacogenomics Market for Academic & Research Institutes, by Country/Region, 2022-2031 (USD Million)
  • Table 26 Global Pharmacogenomics Market for Other End Users, by Country/Region, 2022-2031 (USD Million)
  • Table 27 Global Pharmacogenomics Market, by Country/Region, 2022-2031 (USD Million)
  • Table 28 North America: Pharmacogenomics Market, by Country, 2022-2031 (USD Million)
  • Table 29 North America: Pharmacogenomics Market, by Offering, 2022-2031 (USD Million)
  • Table 30 North America: Pharmacogenomics Market, by Technology, 2022-2031 (USD Million)
  • Table 31 North America: Pharmacogenomics Market, by Application, 2022-2031 (USD Million)
  • Table 32 North America: Pharmacogenomics Market, by End User, 2022-2031 (USD Million)
  • Table 33 U.S.: Pharmacogenomics Market, by Offering, 2022-2031 (USD Million)
  • Table 34 U.S.: Pharmacogenomics Market, by Technology, 2022-2031 (USD Million)
  • Table 35 U.S.: Pharmacogenomics Market, by Application, 2022-2031 (USD Million)
  • Table 36 U.S.: Pharmacogenomics Market, by End User, 2022-2031 (USD Million)
  • Table 37 Canada: Diabetes Prevalence 2023 Vs 2033
  • Table 38 Canada: Pharmacogenomics Market, by Offering, 2022-2031 (USD Million)
  • Table 39 Canada: Pharmacogenomics Market, by Technology, 2022-2031 (USD Million)
  • Table 40 Canada: Pharmacogenomics Market, by Application, 2022-2031 (USD Million)
  • Table 41 Canada: Pharmacogenomics Market, by End User, 2022-2031 (USD Million)
  • Table 42 Europe: Ubiquitous Pharmacogenomics Contributions (USD Million)
  • Table 43 Europe: Pharmacogenomics Market, by Country/Region, 2022-2031 (USD Million)
  • Table 44 Europe: Pharmacogenomics Market, by Offering, 2022-2031 (USD Million)
  • Table 45 Europe: Pharmacogenomics Market, by Technology, 2022-2031 (USD Million)
  • Table 46 Europe: Pharmacogenomics Market, by Application, 2022-2031 (USD Million)
  • Table 47 Europe: Pharmacogenomics Market, by End User, 2022-2031 (USD Million)
  • Table 48 Germany: Pharmacogenomics Market, by Offering, 2022-2031 (USD Million)
  • Table 49 Germany: Pharmacogenomics Market, by Technology, 2022-2031 (USD Million)
  • Table 50 Germany: Pharmacogenomics Market, by Application, 2022-2031 (USD Million)
  • Table 51 Germany: Pharmacogenomics Market, by End User, 2022-2031 (USD Million)
  • Table 52 France: Pharmacogenomics Market, by Offering, 2022-2031 (USD Million)
  • Table 53 France: Pharmacogenomics Market, by Technology, 2022-2031 (USD Million)
  • Table 54 France: Pharmacogenomics Market, by Application, 2022-2031 (USD Million)
  • Table 55 France: Pharmacogenomics Market, by End User, 2022-2031 (USD Million)
  • Table 56 U.K. Pharmacogenomics Market, by Offering, 2022-2031 (USD Million)
  • Table 57 U.K. Pharmacogenomics Market, by Technology, 2022-2031 (USD Million)
  • Table 58 U.K. Pharmacogenomics Market, by Application, 2022-2031 (USD Million)
  • Table 59 U.K. Pharmacogenomics Market, by End User, 2022-2031 (USD Million)
  • Table 60 Italy: Pharmacogenomics Market, by Offering, 2022-2031 (USD Million)
  • Table 61 Italy: Pharmacogenomics Market, by Technology, 2022-2031 (USD Million)
  • Table 62 Italy: Pharmacogenomics Market, by Application, 2022-2031 (USD Million)
  • Table 63 Italy: Pharmacogenomics Market, by End User, 2022-2031 (USD Million)
  • Table 64 Spain: Pharmacogenomics Market, by Offering, 2022-2031 (USD Million)
  • Table 65 Spain: Pharmacogenomics Market, by Technology, 2022-2031 (USD Million)
  • Table 66 Spain: Pharmacogenomics Market, by Application, 2022-2031 (USD Million)
  • Table 67 Spain: Pharmacogenomics Market, by End User, 2022-2031 (USD Million)
  • Table 68 Rest of Europe: Pharmacogenomics Market, by Offering, 2022-2031 (USD Million)
  • Table 69 Rest of Europe: Pharmacogenomics Market, by Technology, 2022-2031 (USD Million)
  • Table 70 Rest of Europe: Pharmacogenomics Market, by Application, 2022-2031 (USD Million)
  • Table 71 Rest of Europe: Pharmacogenomics Market, by End User, 2022-2031 (USD Million)
  • Table 72 Asia-Pacific: Pharmacogenomics Market, by Country/Region, 2022-2031 (USD Million)
  • Table 73 Asia-Pacific: Pharmacogenomics Market, by Offering, 2022-2031 (USD Million)
  • Table 74 Asia-Pacific: Pharmacogenomics Market, by Technology, 2022-2031 (USD Million)
  • Table 75 Asia-Pacific: Pharmacogenomics Market, by Application, 2022-2031 (USD Million)
  • Table 76 Asia-Pacific: Pharmacogenomics Market, by End User, 2022-2031 (USD Million)
  • Table 77 China: Pharmacogenomics Market, by Offering, 2022-2031 (USD Million)
  • Table 78 China: Pharmacogenomics Market, by Technology, 2022-2031 (USD Million)
  • Table 79 China: Pharmacogenomics Market, by Application, 2022-2031 (USD Million)
  • Table 80 China: Pharmacogenomics Market, by End User, 2022-2031 (USD Million)
  • Table 81 Japan: Pharmacogenomics Market, by Offering, 2022-2031 (USD Million)
  • Table 82 Japan: Pharmacogenomics Market, by Technology, 2022-2031 (USD Million)
  • Table 83 Japan: Pharmacogenomics Market, by Application, 2022-2031 (USD Million)
  • Table 84 Japan: Pharmacogenomics Market, by End User, 2022-2031 (USD Million)
  • Table 85 India: Pharmacogenomics Market, by Offering, 2022-2031 (USD Million)
  • Table 86 India: Pharmacogenomics Market, by Technology, 2022-2031 (USD Million)
  • Table 87 India: Pharmacogenomics Market, by Application, 2022-2031 (USD Million)
  • Table 88 India: Pharmacogenomics Market, by End User, 2022-2031 (USD Million)
  • Table 89 Rest of Asia-Pacific: Pharmacogenomics Market, by Offering, 2022-2031 (USD Million)
  • Table 90 Rest of Asia-Pacific: Pharmacogenomics Market, by Technology, 2022-2031 (USD Million)
  • Table 91 Rest of Asia-Pacific: Pharmacogenomics Market, by Application, 2022-2031 (USD Million)
  • Table 92 Rest of Asia-Pacific: Pharmacogenomics Market, by End User, 2022-2031 (USD Million)
  • Table 93 Latin America: Pharmacogenomics Market, by Offering, 2022-2031 (USD Million)
  • Table 94 Latin America: Pharmacogenomics Market, by Technology, 2022-2031 (USD Million)
  • Table 95 Latin America: Pharmacogenomics Market, by Application, 2022-2031 (USD Million)
  • Table 96 Latin America: Pharmacogenomics Market, by End User, 2022-2031 (USD Million)
  • Table 97 Middle East & Africa: Pharmacogenomics Market, by Offering, 2022-2031 (USD Million)
  • Table 98 Middle East & Africa: Pharmacogenomics Market, by Technology, 2022-2031 (USD Million)
  • Table 99 Middle East & Africa: Pharmacogenomics Market, by Application, 2022-2031 (USD Million)
  • Table 100 Middle East & Africa: Pharmacogenomics Market, by End User, 2022-2031 (USD Million)
  • Table 101 Recent Developments, by Company (2020-2023)

LIST OF FIGURES

  • Figure 1 Research Process
  • Figure 2 Secondary Sources Referenced for This Study
  • Figure 3 Primary Research Techniques
  • Figure 4 Key Executives Interviewed
  • Figure 5 Breakdown of Primary Interviews (Supply-side & Demand-side)
  • Figure 6 Market Sizing and Growth Forecast Approach
  • Figure 7 Global Pharmacogenomics Market, by Offerings, 2024 Vs. 2031 (USD Million)
  • Figure 8 Global Pharmacogenomics Market, by Technology, 2024 Vs. 2031 (USD Million)
  • Figure 9 Global Pharmacogenomics Market, by Application, 2024 Vs. 2031 (USD Million)
  • Figure 10 Global Pharmacogenomics Market, by End User, 2024 Vs. 2031 (USD Million)
  • Figure 11 Global Pharmacogenomics Market, by Geography
  • Figure 12 Impact Analysis of Market Dynamics
  • Figure 13 Percentage Share of U.S. FDA-Approved PGx-Labeled Drugs, by Application (As of June 2023)
  • Figure 14 U.S.: Number of Personalized Medicines on The Market, 2008-2020
  • Figure 15 Molecular and Cell-Based Therapies (As a Percentage of Total FDA-Approved Therapies), 2015-2021
  • Figure 16 Global Estimated Number of New Cancer Cases, 2020-2040 (In Million)
  • Figure 17 Genome Sequencing Costs, 2010-2022 (USD)
  • Figure 18 USFDA Regulatory Pathways for Pharmacogenomics Products
  • Figure 19 EU Regulatory Pathway - IVDR 2017/746
  • Figure 20 China: Medical Device Classification and Pre-Market Requirements for IVD Devices
  • Figure 21 Porter's Five Forces Analysis
  • Figure 22 Global Pharmacogenomics Market, by Offering, 2024 Vs. 2031 (USD Million)
  • Figure 23 Global Estimated Number of New Cancer Cases (2020-2040) (Million)
  • Figure 24 Global Pharmacogenomics Market, by Technology, 2024 Vs. 2031 (USD Million)
  • Figure 25 Global Pharmacogenomics Market, by Application, 2024 Vs. 2031 (USD Million)
  • Figure 26 Estimated Number of New Cancer Cases, 2020 Vs. 2040
  • Figure 27 Global Pharmacogenomics Market, by End User, 2023 Vs. 2030 (USD Million)
  • Figure 28 Global Pharmacogenomics Market Assessment, by Country/Region, 2024-2031 (USD Million)
  • Figure 29 North America: Pharmacogenomics Market Snapshot
  • Figure 30 Precision Medicine Research Funding To NIH, 2018-2024 (USD Million)
  • Figure 31 Europe: Pharmacogenomics Market Snapshot
  • Figure 32 Germany: Estimated Number of New Cancer Cases, 2020-2035 (In Thousand)
  • Figure 33 France: Total Number of People with Dementia, 2018-2050 (In Thousands)
  • Figure 34 Asia-Pacific: Pharmacogenomics Market Snapshot
  • Figure 35 Key Growth Strategies Adopted by Leading Market Players (2020-2023)
  • Figure 36 Pharmacogenomics Market: Competitive Benchmarking, by Offering
  • Figure 37 Pharmacogenomics Market: Competitive Benchmarking, by Region
  • Figure 38 Competitive Dashboard: Pharmacogenomics Market
  • Figure 39 Global Pharmacogenomics Market Ranking, by Key Players (2023)
  • Figure 40 F. Hoffmann La-Roche Ltd.: Financial Snapshot (2022)
  • Figure 41 Thermo Fisher Scientific, Inc.: Financial Overview (2022)
  • Figure 42 Illumina, Inc.: Financial Overview (2022)
  • Figure 43 Danaher Corporation: Financial Overview (2022)
  • Figure 44 Agilent Technologies, Inc.: Financial Snapshot (2023)
  • Figure 45 Qiagen N.V.: Financial Snapshot (2022)
  • Figure 46 Abbott Laboratories: Financial Overview (2022)
  • Figure 47 Bio-Rad Laboratories, Inc.: Financial Overview (2022)
  • Figure 48 PerkinElmer, Inc.: Financial Overview (2022)
  • Figure 49 Pacific Biosciences of California, Inc.: Financial Overview (2022)